Ovarian Cancer Clinical Trials (as in March 2017)

ENGOT-ov1/MITO-8

Leading Group: MITO

Clinical Trial Study: A phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval in patients with ovarian cancer recurring between 6 and 12 months after previous platinum based chemotherapy (S. Pignata)

Final number of patients: 215 (no longer recruiting)

Participating groups:

AGO, BGOG, MANGO

 

 

ENGOT- ov5/INOVATYON

Leading group: ManGO

Clinical Trial Study: Phase III multicenter, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum (N. Colombo)

Number of patients accrued: 496 randomised (recruitment continues)

Planned number of patients: 588

Participating groups:

A-AGO, BGOG, DGOG, GEICO, NCRI, NOGGO, NSGO, SAKK

 

 

ENGOT-ov10/MITO

Leading group: MITO

Clinical Trial Study: Weekly vs every 3-week carboplatin and paclitaxel  in patients with ovarian cancer: Phase III multicenter trial

Final number of patients: 822 (closed to recruitment)

Participating groups:

GINECO, MaNGO

 

 

ENGOT-ov 13/NCRI/ICON8

Leading group: NCRI

Clinical Trial Study: An international multi-stage randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian cancer (J. Ledermann)

Final number of patients: 1566 (closed to recruitment)

Participating groups:

Cancer Trials Ireland, (ANZGOG, CTU EOC, GICOM, KGOG,)

 

 

ENGOT-ov 13/NCRI/ICON8B

Leading group: NCRI

Clinical Trial Study: An international multi-stage randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian cancer (J. Ledermann)

Number of patients accrued: 355

Planned number of patients: 1170

Participating groups:

Cancer Trials Ireland, (ANZGOG, GICOM, KGOG, CTU EOC)

 

 

ENGOT-ov15/AGO-OVAR 17

Leading group: AGO

Clinical Trial Study: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. The BOOST (Bevacizumab Ovarian Optiam Standard Treatment) Trial (J. Pfisterer)

Number of patients accrued: 927 (closed to recruitment)

Participating Groups:

GINECO, NSGO

 

 

ENGOT-ov18/AGO-OVAR 2.21

Leading group: AGO

Clinical Trial Study: A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer (J. Pfisterer)

Final number of patients: 682

Participating groups:

A-AGO, GINECO, SGCTG, (ANZGOG)

 

 

ENGOT-ov20/AGO-OVAR OP.4/ Desktop 3

Leading group: AGO

Clinical Trial Study: Randomised trial investigating secondary debulking versus no-secondary debulking in platin sensitive disease (A. du Bois)

Final number of patients: 408 (last patient recruited in March 2015)

Participating groups:

A-AGO, BGOG, GEICO, GINECO, MaNGO, MITO, NSGO, (CRCTU UK, KGOG, SGOG)

 

 

ENGOT-ov23/GINECO/EWOC-1

Leading group: GINECO

Clinical Trial Study: Multicenter, randomized trial of carboplatin +/-paclitaxel in vulnerable elderly patients with stage IIB- IV advanced ovarian cancer

Number of patients accrued: 111

Planned number of patients: 240

Participating groups: MITO, NSGO

 

 

ENGOT-ov24/NSGO/AVANOVA

Leading group: NSGO

Clinical Trial Study: Niraparib and/or Niraparib-bevacizumab combination against bevacizumab alone in Women with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer

Number of patients accrued: 94

Planned number of patients: 612

Participating groups:

GEICO, ISGO, MITO

 

 

ENGOT-ov25/GINECO/PAOLA

Leading group: GINECO

Clinical Trial Study: Phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab

Number of patients accrued: 650

Planned number of patients: 760

Participating groups:

A-AGO, AGO, BGOG, GEICO MaNGO, MITO, NSGO, (GOTIC)

 

 

ENGOT-ov26/GEICO/1509 - PRIMA study

Leading group: GEICO

Clinical Trial Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Number of patients accrued: 305

Planned number of patients: 530

Participating groups:

AGO, BGOG, Cancer Trials Ireland, GINECO, ISGO, MITO, NSGO

 

 

ENGOT-ov27/BGOG-ov18

Leading group: BGOG

Clinical Trial Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

Number of patients accrued: 113

Planned number of patients: 210

Participating groups:

GEICO, MITO, NOGGO

 

 

ENGOT-ov29/GINECO/ATALANTE

Leading group: GINECO

Clinical Trial Study: Randomized trial comparing atezolizumab versus placebo in patients with 1st or 2nd platinum-sensitive relapse of OC treated with carboplatin combination + bevacizumab

Number of patients accrued: 90

Planned number of patients: 405

Participating groups:

A-AGO, AGO, BGOG, CEECOG, GEICO, ISGO, NSGO

 

 

ENGOT-ov30/NSGO/UMB1

Leading group: NSGO

Clinical Trial Study: Umbrella Trial in Recurrent Ovarian Cancer

Number of patients accrued: 75

Planned number of patients: N.A.

Participating groups:

BGOG, EORTC, SGCTG, (ANZGOG, COGI, GOTIC, PMHC)

 

 

ENGOT-ov31/AGO Ovar OP.3/Lion

Leading group: AGO

Clinical Trial Study: Lion: Lymphadenectomy In Ovarian Neoplasms

Number of patients accrued: 650

Planned number of patients: 640

Participating groups:

A-AGO, BGOG, MaNGO, MITO

 

 

ENGOT-ov32/MITO 23

Leading group: MITO

Clinical Trial Study: Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients

Number of patients accrued: 46

Planned number of patients: 244

Participating groups:

MaNGO, GEICO under discussion

 

 

ENGOT-ov33/AGO Ovar OP.7/ TRUST

Leading group: AGO

Clinical Trial Study:

TRUST: Trial on Radical Upfront Surgical Therapy

Number of patients accrued: 52

Planned number of patients: N.A.

Participating groups:

GINECO, MaNGO, MITO, NOGGO

 

 

ENGOT-ov34/AGO Ovar 2.29

Leading group: AGO

Clinical Trial Study: Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial

Number of patients accrued: TBA

Planned number of patients: TBA

Participating groups: under discussion

 

 

ENGOT-ov 35/NCRI/ICON 9

Leading group: NCRI

Clinical Trial Study: An international phase III randomised double-blind study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy in patients with relapsed platinum-sensitive ovarian cancer following platinum-based chemotherapy with cediranib

Number of patients accrued: N.A.

Planned number of patients: 610

Participating groups:

GEICO, MaNGO, MITO, (ANZGOG, NCIC)

 

 

ENGOT-ov36/SGCTG – NSGO

Leading group: SGCTG

Clinical Trial Study: A phase II trial of a triple angiokinase inhibitor (BIBF1120) in the treatment of patients with recurrent clear cell ovarian cancer

Number of patients accrued: 27

Planned number of patients: 120

Participating groups:

EORTC, GINECO, NCRI, NSGO

 

 

ENGOT-ov37/GEICO/CERULEAN

Leading group: GEICO

Clinical Trial Study: CERULEAN: A randomized, double-blind Phase III trial of CRLX101 + weekly paclitaxel versus CRLX101 vehicle + weekly paclitaxel in patients with platinum-resistant ovarian cancer

Number of patients accrued: will start in 2017

Planned number of patients: 320

Participating groups: under discussion

 

 

ENGOT-ov38/GINECO/OReO

Leading group: GINECO

Clinical Trial Study: Double blind phase IIIb study: Olaparib Retreatment in late recurrent Ovarian cancer

Number of patients accrued: will start in April 2017

Planned number of patients: 416

Participating groups:

AGO, BGOG, GEICO, ISGO, MITO, NSGO

 

 

ENGOT-ov39/MITO/ATEZO

Leading group: MITO

Clinical Trial Study: A Phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed Stage III or Stage IV ovarian, fallopian tube, or primary peritoneal cancer

Planned number of patients: 1300

Participating groups:

A-AGO, AGO, BGOG, MaNGO, NSGO, CEEGOG, GEICO, GINECO, HeCOG, PGOG, TRSGO

 

 

ENGOT-ov40/NOGGO S13/Expression VI

Leading group: NOGGO

Clinical Trial Study: Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer

Number of patients accrued: 12

Planned number of patients: 100-200 per participating country

Participating groups:

A-AGO, BGOG, MITO, NSGO, TRSGO, (Romania)

Up Coming ENGOT Meeting

Frankfurt, Germany, October 12-13, 2017

Don't miss out on the latest updates

Save the Date!

You May Also Like

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

CLINICAL TRIALS

Latest Published Research

 

Read More

FOR PATIENTS

Key Insights

 

Read More

ESGO 2017 Congress

Clinical Trials Session

 

Read More